UK backs ranibizumab (Lucentis) for new use after Novartis cuts price
LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to ranibizumab (Lucentis)
to treat diabetic macular edema after Swiss drugmaker Novartis offered it at a discount to the National Health
Service.
Source: Modern Medicine - Category: Journals (General) Source Type: news
More News: Diabetes | Endocrinology | General Medicine | Health | Lucentis | National Health Service (NHS) | Ranibizumab Injection | UK Health